US pharma giant Merck & Co (NYSE: MRK) raised and narrowed its forecasts for profit and sales for 2024 in presenting its first-quarter 2024 financial results.
The company’s sales grew by 9% in the quarter to $15.78 billion, beating analysts’ expectations of $15.2 billion, with the immuno-oncology drug Keytruda (pembrolizumab) a major factor in this.
"Important opportunities ahead of us across all areas of our business"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze